Back to research database
Supplements
Omega-3 fatty acid supplements and cardiovascular outcomes
Moderate evidenceIndependentNew England Journal of Medicine, 2019
Sample size
25,871
participants
Study duration
5.3 years
Study type
Randomised controlled trial
Marketing vs evidence
Many omega-3 supplement brands continue to market cardiovascular benefits broadly despite RCT evidence suggesting limited benefit for the general population. Benefits appear specific to high-risk groups with elevated triglycerides.
Plain English summary
Recent large randomised controlled trials have produced mixed results on omega-3 supplementation for cardiovascular disease prevention, revising earlier optimistic findings. The picture is more nuanced than widespread supplement marketing suggests.
Key findings
- The VITAL trial (25,871 participants) found no significant reduction in major cardiovascular events from omega-3 supplementation in a general adult population
- High-dose supplements (4g/day) showed benefits in patients with elevated triglycerides specifically
- Dietary omega-3 from fish remains associated with better cardiovascular outcomes than supplementation
- Earlier positive trials used different formulations and populations, complicating comparison